Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
about
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversionDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Current perspectives on cardiovascular outcome trials in diabetesClosing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondRisk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study.Type 1 diabetes mellitus.Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.Coronary artery disease and diabetes mellitus.The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation.cAMP-dependent Protein Kinase (PKA) Signaling Is Impaired in the Diabetic HeartRisk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialAssociations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus.Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort StudyHeart failure event definitions in drug trials in patients with type 2 diabetes.Alternative Interventions to Prevent Oxidative Damage following Ischemia/ReperfusionWhy do statins reduce cardiovascular disease more than other lipid modulating therapies?Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.Type 2 Diabetes and Heart Failure: Challenges and Solutions.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice.Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study in England.Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.Cardio-renal protection with empagliflozin.Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial.Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy.Clinical features, management and mortality in diabetic and non-diabetic patients with heart failure - observations from the COMMIT-HF registry.Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world.Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.
P2860
Q26740171-E1F7B4F4-661A-4C5C-A0FB-B34555435FB1Q26749281-5CA61D8A-39C3-48B8-80AE-F997F4A10AF1Q26750510-42D499BC-622C-4D3B-8550-59AE641436B0Q27301948-1362A53D-610C-4507-8DA1-8255119C399FQ28066006-7753A4BD-B5F9-4888-8DAA-CEC6C52B2F67Q28075848-082B81A3-1DF4-4F70-8E11-882BC29FA680Q30234586-AD3981BC-6C04-4443-BC0A-44317ECC03C2Q30235021-3DF680BF-6C33-4B98-B5D1-DC1869585D05Q30240823-FA0D9D83-DDD5-480D-8F3E-B3BD34CF2FBBQ30250020-DB9AD340-097D-4D86-B9C1-6C7069A6F61DQ30846870-42D0BF72-75BB-43FC-B2CC-65A69611F349Q33660548-67F8BD7B-D506-4F38-820B-0BED96DF36E9Q33708984-1EB4F781-F377-436D-873F-757B48F0ED41Q36355228-1A3FAC26-C64D-4972-A68E-18E1CC4A71A6Q36417449-131127B1-1BDF-430A-AE8B-B78F4EF0C136Q36444031-C66ED4D1-DA01-4547-AABF-E46C8629B781Q36477865-5C8DE3F3-226C-42E8-891D-9645CB9E15BDQ37337371-ACB0FBB2-3D52-4512-8A69-085E8AC7F264Q37527438-7E86BB40-08E9-44F1-80F0-724516985CBDQ37573665-1D52245E-2055-4098-9A85-EA17F340C28DQ37578724-80A7F2E8-640B-4EB4-98D2-73C390FB81C2Q38253965-B049B29E-C009-4E5E-8E4F-B8387D38C3B6Q38427211-8FC66865-4800-4033-9F0E-BC33F0252F97Q38651423-BA9DB458-798E-4557-8E88-5F7B203A2FC2Q38833312-0D012ED5-B456-49CD-B866-8DB013A7F652Q38859858-6AAAD7CC-A282-4EE0-999B-6C3845C80CF3Q38885540-7730ED73-2921-40F3-BD91-E8C09D5B257BQ38927264-259AEF12-0698-4D30-9149-BFD2263D0060Q38960765-9AD54832-B275-40DD-8CF6-BBA67E9C0C87Q38982581-0A00D376-BC22-49D7-B4CD-7B616F2F949CQ39247252-F96459E0-3E48-4FD0-BFC8-3B7C34A5C63EQ39480831-343A8B69-7041-4243-9376-56FA50041842Q40132501-C3A74381-5730-495E-9251-A2BF6097C66BQ40443143-29AE0603-7182-42D0-9B4F-F0500C60E104Q41573388-8AED8988-6B97-4730-A804-0C7BC8C815C4Q41713305-56D4A289-F29F-4B8C-8F35-A7550E816BB3Q47114494-6FBA4C28-0DF5-4830-94E5-83711F1B6D6BQ47154265-31F248FA-00A4-4CBC-BC4F-0986720ED662Q47771118-F080615E-1061-4E27-AE0C-9B907639C2F2Q47785505-AF53D3AC-1F04-4B1B-AC25-D4BC6BA892BB
P2860
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
@en
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
@nl
type
label
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
@en
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
@nl
prefLabel
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
@en
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
@nl
P50
P1476
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
@en
P2093
Marc A Pfeffer
P304
P356
10.1016/S2213-8587(14)70031-2
P577
2014-03-13T00:00:00Z